Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

With the readout of UNVEIL-IT® Phase 2, which evaluates VS-01, also targeted in the second half of 2025, up to 4 clinical datasets are expected to be released by GENFIT before the end of this year ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...